Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection

Moore, Anne; Dora, Emery G; Peinovich, Nadine; Tucker, Kiersten P.; Lin, Karen; Cortese, Mario; Tucker, Sean N.

doi:10.1101/2020.09.04.283853

Cited by 19 publications

(15 citation statements)

References 54 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, it was concluded that stabilizing the spike protein in its pre-fusion conformation is not necessary in nucleic acid vaccines, since it does not induce higher neutralizing antibody (NAb) titers in murine models compared to the non-stabilized version. Nevertheless, this has not been reported in other Ad vaccines 99,100 .…”

Section: Adenoviral Vector Vaccines For Sars-cov-2mentioning

confidence: 67%

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

et al. 2021

View full text Add to dashboard Cite

Adenoviral vectors have been explored as vaccine agents for a range of infectious diseases, and their ability to induce a potent and balanced immune response made them logical candidates to apply to the COVID-19 pandemic. The unique molecular characteristics of these vectors enabled the rapid development of vaccines with advanced designs capable of overcoming the biological challenges faced by early adenoviral vector systems. These successes and the urgency of the COVID-19 situation have resulted in a flurry of candidate adenoviral vector vaccines for COVID-19 from both academia and industry. These vaccines represent some of the lead candidates currently supported by Operation Warp Speed and other government agencies for rapid translational development. This review details adenoviral vector COVID-19 vaccines currently in human clinical trials and provides an overview of the new technologies employed in their design. As these vaccines have formed a cornerstone of the COVID-19 global vaccination campaign, this review provides a full consideration of the impact and development of this emerging platform.

show abstract

Section: Adenoviral Vector Vaccines For Sars-cov-2mentioning

confidence: 67%

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Access to vaccines heavily depends on their formulations which are often delicate and require storage in coolers or cryotanks, presenting challenges in transportation and cold-chain distribution [ 243 ]. An oral adenovirus based-vaccine for SARS-CoV-2 S protein has been developed in response to these challenges, offering advantages of utilizing mucosal immunity with ease of storage and needle-free applications [ 244 ].…”

Section: Covid-19 Vaccinesmentioning

confidence: 99%

COVID-19 vaccines: The status and perspectives in delivery points of view

Chung

Thone

Kwon

2021

Advanced Drug Delivery Reviews

308

265

View full text Add to dashboard Cite

Due to the high prevalence and long incubation periods often without symptoms, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals globally, causing the coronavirus disease 2019 (COVID-19) pandemic. Even with the recent approval of the anti-viral drug, remdesivir, and Emergency Use Authorization of monoclonal antibodies against S protein, bamlanivimab and casirimab/imdevimab, efficient and safe COVID-19 vaccines are still desperately demanded not only to prevent its spread but also to restore social and economic activities via generating mass immunization. Recent Emergency Use Authorization of Pfizer and BioNTech’s mRNA vaccine may provide a pathway forward, but monitoring of long-term immunity is still required, and diverse candidates are still under development. As the knowledge of SARS-CoV-2 pathogenesis and interactions with the immune system continues to evolve, a variety of drug candidates are under investigation and in clinical trials. Potential vaccines and therapeutics against COVID-19 include repurposed drugs, monoclonal antibodies, antiviral and antigenic proteins, peptides, and genetically engineered viruses. This paper reviews virology and immunology of SARS-CoV-2, alternative therapies for COVID-19 to vaccination, principles and design considerations in COVID-19 vaccine development, and the promises and roles of vaccine carriers in addressing the unique immunopathological challenges presented by the disease.

show abstract

“…The company Vaxart has developed a vaccine that uses a nrVV adenovirus type-5 (Ad5), that encodes the complete S glycoprotein as it is expressed by the original SARS-CoV-2, preserving all the components of the S1 and S2 subunits ( 64 ). Similarly, the company Arcturus Therapeutics has used a complete S glycoprotein without modifications, however, they have opted for technologies of a self-replicating mRNA ready for translation ( 65 ).…”

Section: S Glycoprotein In Sars-cov-2 Vaccinesmentioning

confidence: 99%

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

et al. 2021

View full text Add to dashboard Cite

Coronavirus 19 Disease (COVID-19) originating in the province of Wuhan, China in 2019, is caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), whose infection in humans causes mild or severe clinical manifestations that mainly affect the respiratory system. So far, the COVID-19 has caused more than 2 million deaths worldwide. SARS-CoV-2 contains the Spike (S) glycoprotein on its surface, which is the main target for current vaccine development because antibodies directed against this protein can neutralize the infection. Companies and academic institutions have developed vaccines based on the S glycoprotein, as well as its antigenic domains and epitopes, which have been proven effective in generating neutralizing antibodies. However, the emergence of new SARS-CoV-2 variants could affect the effectiveness of vaccines. Here, we review the different types of vaccines designed and developed against SARS-CoV-2, placing emphasis on whether they are based on the complete S glycoprotein, its antigenic domains such as the receptor-binding domain (RBD) or short epitopes within the S glycoprotein. We also review and discuss the possible effectiveness of these vaccines against emerging SARS-CoV-2 variants.

show abstract

Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection

Cited by 19 publications

References 54 publications

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

COVID-19 vaccines: The status and perspectives in delivery points of view

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

Contact Info

Product

Resources

About